Antibiotic prescribing practices during the COVID-19 pandemic: A post-hoc analysis of the Adaptive COVID-19 Treatment Trial

Résumé fourni par la source

Abstract Background The COVID-19 pandemic exacerbated antibiotic overuse; however, gaps remain regarding the timing of administration and whether prescribing is supported by evidence of bacterial infection. Methods Antibiotic use was described within the Adaptive COVID-19 Treatment Trial (ACTT), a series of randomized controlled therapeutics trials in adults hospitalized with COVID-19 from Feb 2020-May 2021. Proportions of participants receiving antibiotics by trial stage were described (overall, pre-randomization, post-randomization). Analyses were repeated for CDC’s National Healthcare Safety Network (NHSN) categories and for antibiotics used for community-acquired pneumonia (CAP) according to IDSA guidelines. In ACTT-2 and ACTT-4, lab culture results were documented for Grade 3 or greater infection adverse events; proportions of antibiotic recipients with a positive culture were compared between trials. Results Most (62%) of the 4,074 participants received at least one antibiotic. Pre-randomization antibiotic use declined across ACTT stages, from 72% in ACTT-1 to 32% in ACTT-4. The largest decrease noted is within the NHSN category for community-acquired infection (decreasing significantly from 49% in ACTT-1 to 24% in ACTT-4). Post-randomization use was lower and declined modestly, from 28% to 18%. The percentage of post-randomization antibiotic recipients with a positive bacterial culture was 18% in ACTT-2 and 18% in ACTT-4. Conclusions Antibiotic use decreased substantially over the first pandemic year, however in-hospital prescribing remained common despite limited microbiologic confirmation of infection. Stewardship efforts during future respiratory viral pandemics should focus on reducing empiric antibiotic use for CAP-like illness at presentation and on strengthening reassessment, diagnostic stewardship, and de-escalation of later in-hospital antibiotic therapy.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.